ResMed Inc. vs Invesco S&P 500 Low Volatility ETF — how do they compare? ResMed Inc. trades at $222.39 (market cap $31.92B), while Invesco S&P 500 Low Volatility ETF trades at $75.6. The key difference: ResMed Inc. pays a 1.2% dividend while Invesco S&P 500 Low Volatility ETF pays none, and Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | SPLV | |
|---|---|---|
Market Cap | $31.92B | — |
Sector | Health | — |
52-Week High | $293.73 | $77.97 |
52-Week Low | $182.82 | $70.30 |
Enterprise Value | $31.28B | — |
Dividend Yield | 1.2% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
SPLV trades at $76.21, down 0.07% with neutral technical signals. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market uncertainty. Recent news highlights its role in diversification as investors seek shelter from tech sell-offs and geopolitical tensions. Moving averages show a bullish trend, while oscillators indicate neutrality, with RSI at 55.45 suggesting balanced momentum.
Outlook: SPLV provides defensive exposure with historical resilience, but reliance on low-volatility factors may lag in bullish markets. Risks include concentrated sector bets and interest rate sensitivity. Analyst sentiment is mixed, reflecting its niche role in risk-averse portfolios.
Trailing returns across standard periods
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →